SCHEMBL3476966

SCHEMBL3476966

O=S(=O)(Nc1ncc(C(F)(F)F)cn1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.54
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 2/20 0.48
XBP1 P17861 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD11B1 P28845 1/20 0.48
OXTR P30559 1/20 0.48
AR P10275 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
TSHR P16473 1/20 0.47
NR1H3 Q13133 1/20 0.47
PKM P14618 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SLC40A1 Q9NP59 1/20 0.46
IL1RN P18510 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3477592 0.81 TSHR (0.51) KMT2ALMNANPSR1MEN1ALDH1A1
SCHEMBL3476657 0.81 POLB (0.61) PPARGKMT2ALMNAMAPTHTT
SCHEMBL1093621 0.80 SLC40A1 (0.51) TSHRSLC40A1
SCHEMBL21753108 0.78 TSHR (0.60) LMNANPSR1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL18307327 0.78 KMT2A (0.49) PPARGKMT2ALMNAMAPTHTT
SCHEMBL332569 0.77 TSHR (0.70) KMT2ALMNANPSR1ALDH1A1KDM4E
SCHEMBL18299091 0.77 KMT2A (0.48) PPARGKMT2ALMNAMAPTHTT
SCHEMBL119177 0.77 KMT2A (0.77) KMT2ALMNAMAPTHTTNPSR1
SCHEMBL2567685 0.75 NR1H3 (0.71) PPARGKMT2ALMNAMAPTNPSR1
SCHEMBL23567060 0.74 LMNA (0.73) KMT2ALMNAMAPTNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 PPARG 1591/4885KMT2A 3314/4885LMNA 2523/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PPARG 1591/4885KMT2A 3314/4885LMNA 2523/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 PPARG 1591/4885KMT2A 3314/4885LMNA 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.